September 2010 Safety Labeling Changes: 37 Medical Product Labels with changes to Warnings, Contraindications, Precautions, Adverse Reactions

[Date Prev][Date Next][Thread Prev][Thread Next][Date Index][Thread Index]

 



Title: September 2010 Safety Labeling Changes: 37 Medical Product Labels with changes to Warnings, Contraindications, Precautions, Adverse Reactions
MedWatch logo MedWatch - The FDA Safety Information and Adverse Event Reporting Program

September 2010 Safety Labeling Changes: 37 Medical Product Labels with changes to Warnings, Contraindications, Precautions, Adverse Reactions

The MedWatch September 2010 Safety Labeling Changes posting includes 37 products with safety labeling changes to the following sections: BOXED WARNINGS, CONTRAINDICATIONS, WARNINGS, PRECAUTIONS, ADVERSE REACTIONS, PATIENT PACKAGE INSERT, and MEDICATION GUIDE.

The "Summary Page" provides a listing of drug names and safety labeling sections revised:

http://www.fda.gov/Safety/MedWatch/SafetyInformation/ucm228392.htm

Clicking on a drug product name in the Summary View will take you to the "detailed view" page, which identifies safety labeling sections and subsections revised, along with a brief summary of new or modified safety information.

The following drugs had modifications to the BOXED WARNINGS, CONTRAINDICATIONS and WARNINGS sections: 
    
Aciphex (rabeprazole sodium)         
Alli (orlistat)      
Altabax (retapamulin)   
Apokyn (apomorphine hydrochloride)
Arava (leflunomide) 
Casodex (bicalutamide)
Combunox (Oxycodone HCl/ibuprofen)
Desferal (deferoxamine mesylate)   
Dexilant (dexlansoprazole)   
Faslodex (fulvestrant)        
Minocin (minocycline hydrochloride)       
Nexium (esomeprazole magnesium)
Nexium I.V. (esomeprazole sodium)    
Noxafil (posaconazole) 
Prevacid (lansoprazole)
Prilosec (omeprazole magnesium)     
Protonix (pantoprazole sodium)
Rotarix (rotavirus vaccine, live, oral)  
Zegerid (omeprazole/sodium bicarbonate)
Zegerid with Magnesium Hydroxide (omeprazole/sodium bicarbonate/magnesium hydroxide)
Zofran (ondansetron hydrochloride)


Tell us what you think: http://survey.foreseeresults.com/survey/display?cid=d509U9xg0gZVxkMRcoMsQg==&sid=link&cpp[date]=10_20_2010_1800&cpp[type]=I

You are encouraged to report all serious adverse events and product quality problems to FDA MedWatch at www.fda.gov/medwatch/report.htm

Update your subscriptions, modify your e-mail address, or stop subscriptions at any time on your Subscriber Preferences Page. You will need to use your e-mail address to log in. If you have questions or problems with the subscription service, please contact support@xxxxxxxxxxxxxxx.

This service is provided to you at no charge by U.S. Food & Drug Administration (FDA).

FDA HHS

U.S. Food & Drug Administration (FDA) · 10903 New Hampshire Ave · Silver Spring, MD 20993 · 800-439-1420


[Index of Archives]     [CDC News]     [NIH News]     [USDA News]     [Steve's Art]     [Camping in Yosemite]     [PhotoForum]     [SB Lupus]     [STB]

  Powered by Linux